Asia Deal Watch: Alentis, PinotBio Team Up On Claudin-1 Targeted ADCs For Cancer
Plus deals involving Hiteck/Visara, ApitBio/Mother’s Pharmaceutical, Triastek/Johnson & Johnson, Ono/Biohaven, Dituo/Roche, Yahong/Theramex, SpyGlass/Santen and Dong-A/Galux.
Scrip - October 16, 2026

Lash Serum Brands Face Safety Data Gap As CIR Rejects Read-Across
The Expert Panel for Cosmetic Ingredient Safety accepted the recommendations for prostaglandin analogues from the Read-Across Working Group, rejecting the use of read-across to support the ingredients’ safety.
HBW Insight - October 16, 2026

Edwards Mitral Valve Device Linked To One Death, One Injury, FDA Warns
The US FDA has issued an early alert for some Commander M delivery systems used with Edwards Lifesciences’ Sapien M3 transcatheter mitral valve replacement system after reports of balloon ruptures during inflation. The company reports three incidents, including one death and one serious injury.
Medtech Insight - October 16, 2026

Estuary Launches With $103m To Advance Kidney-Directed Gene Therapies
Estuary Biotherapeutics raised a $93m series A round to take its two lead programs for autosomal dominant polycystic kidney disease into the clinic in 2027 and 2028.
Scrip - October 16, 2026

Iovance Leads Mid-Sized Rising Stars In 2026
A rundown of the ten biggest mid-cap risers and decliners of the year to date, with catalysts which could shape big pharma’s M&A target list
Scrip - October 16, 2026

Cardiac Device Trials To Watch: Four Readouts That Test Whether Early Signals Hold Up
Abbott's TECTONIC data at TCT, BiVACOR's artificial heart expansion, Medtronic's Sphere-9 VT push and Corvia's RESPONDER-HF headline a pivotal stretch for cardiac device innovation.
Medtech Insight - October 16, 2026

Mahl Takes Charge At Fresenius Kabi As Antonelli Departs
Fresenius Kabi has announced a leadership change that will see Marc-Alexander Mahl take over responsibility of the business from current CEO Pierluigi Antonelli at the start of November. Meanwhile, Fresenius chief financial officer Sara Hennicken has seen her contract extended by another five years.
Generics Bulletin - October 16, 2026

Callio Needs ‘Next Bolus Of Capital’ Soon As Dual-Payload ADCs Heat Up
The new CEO of Callio Therapeutics, which has been on the vanguard of companies focused on dual-payload ADCs, talks to Scrip in an exclusive interview about his priorities, including plans to raise funds next year.
Scrip - October 16, 2026

EMA Gives Green Light To EU-Wide Switch Of Opioid Overdose Spray Nyxoid
The European Medicines Agency’s human medicines committee has backed making naloxone nasal spray Nyxoid available without prescription across all EU member states. Applicant Mundipharma says approval would meet a "significant need" to widen access to an emergency treatment for opioid overdose.
HBW Insight - October 16, 2026

Faster Decisions And Earlier Access: UK Generics Industry Welcomes MHRA’s 2030 Targets
Medicines UK has welcomed targets set as part of the newly-unveiled MHRA Strategy 2030, including making faster decisions on generics and biosimilars and also deepening engagement with international markets such as India.
Generics Bulletin - October 16, 2026

Beyond AlphaFold: Immuto Bets Protein Conformations Hold The Next Cancer Targets
Immuto Scientific bets reading protein shapes on living tumor cells can steer antibodies to targets that genomics and expression profiling miss and the company has partnered Daiichi Sankyo and UW-Madison on this basis, Immuto co-founder Daniel says.
In Vivo - October 16, 2026

ProKidney Is Betting A Cell Therapy Phase III Readout Can Fund Its Way To Market
Pivotal data are due in the second quarter of 2027, around when the company’s money is guided to run out. CEO Bruce Culleton spoke to In Vivo on the science, the procedure and the balance sheet.
In Vivo - October 16, 2026

US FDA Wants Advisory Committee Members, But Not Voting Consumer Reps
A nationwide nomination push is a sharp break from former Commissioner Martin Makary’s aversion to advisory committees, even as charter renewals have quietly moved most drug and biologic consumer representative seats to nonvoting status.
HBW Insight - October 16, 2026